Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Fibroblast Activation Protein Inhibitor Theranostics: The Case for Use in Sarcoma.
Hamacher R, Lanzafame H, Mavroeidi IA, Pabst KM, Kessler L, Cheung PF, Bauer S, Herrmann K, Schildhaus HU, Siveke JT, Fendler WP. Hamacher R, et al. Among authors: lanzafame h. PET Clin. 2023 Jul;18(3):361-367. doi: 10.1016/j.cpet.2023.02.008. Epub 2023 Mar 28. PET Clin. 2023. PMID: 36997366 Review.
Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After Prostatectomy.
Zamboglou C, Strouthos I, Sahlmann J, Farolfi A, Serani F, Medici F, Cavallini L, Morganti AG, Trapp C, Koerber SA, Peeken JC, Vogel MME, Schiller K, Combs SE, Eiber M, Vrachimis A, Ferentinos K, Spohn SKB, Kirste S, Gratzke C, Ruf J, Grosu AL, Ceci F, Fendler WP, Miksch J, Kroeze S, Guckenberger M, Lanzafame H, Fanti S, Hruby G, Wiegel T, Emmett L, Schmidt-Hegemann NS, Henkenberens C. Zamboglou C, et al. Among authors: lanzafame h. Int J Radiat Oncol Biol Phys. 2022 Aug 1;113(5):1015-1024. doi: 10.1016/j.ijrobp.2022.04.048. Epub 2022 Jun 3. Int J Radiat Oncol Biol Phys. 2022. PMID: 35659629
Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study.
Scharl S, Zamboglou C, Strouthos I, Farolfi A, Serani F, Lanzafame H, Giuseppe Morganti A, Trapp C, Koerber SA, Debus J, Peeken JC, Vogel MME, Vrachimis A, Spohn SKB, Ruf J, Grosu AL, Ceci F, Fendler WP, Bartenstein P, Kroeze SGC, Guckenberger M, Krafcsik M, Klopscheck C, Fanti S, Hruby G, Emmett L, Belka C, Stief C, Schmidt-Hegemann NS, Henkenberens C, Mayer B, Miksch J, Shelan M, Aebersold DM, Thamm R, Wiegel T. Scharl S, et al. Among authors: lanzafame h. Radiother Oncol. 2023 Jul;184:109678. doi: 10.1016/j.radonc.2023.109678. Epub 2023 May 3. Radiother Oncol. 2023. PMID: 37146766
The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy-a multicenter retrospective analysis.
Spohn SKB, Farolfi A, Schandeler S, Vogel MME, Ruf J, Mix M, Kirste S, Ceci F, Fanti S, Lanzafame H, Serani F, Gratzke C, Sigle A, Combs SE, Bernhardt D, Gschwend JE, Buchner JA, Trapp C, Belka C, Bartenstein P, Unterrainer L, Unterrainer M, Eiber M, Nekolla SG, Schiller K, Grosu AL, Schmidt-Hegemann NS, Zamboglou C, Peeken JC. Spohn SKB, et al. Among authors: lanzafame h. Eur J Nucl Med Mol Imaging. 2022 Dec;50(1):218-227. doi: 10.1007/s00259-022-05931-5. Epub 2022 Aug 19. Eur J Nucl Med Mol Imaging. 2022. PMID: 35984452 Free PMC article.
BRAFV600E mutation is associated with increased prevalence of contralateral lymph-node metastases in low and low-to-intermediate risk papillary thyroid cancer.
Campennì A, Ruggeri RM, Giuffrè G, Siracusa M, Alibrandi A, Cardile D, La Torre F, Lanzafame H, Giacoppo G, Ieni A, Trimarchi F, Tuccari G, Baldari S. Campennì A, et al. Among authors: lanzafame h. Nucl Med Commun. 2021 Jun 1;42(6):611-618. doi: 10.1097/MNM.0000000000001386. Nucl Med Commun. 2021. PMID: 33625185
68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy.
Lanzafame H, Mavroeidi IA, Pabst KM, Desaulniers M, Ingenwerth M, Hirmas N, Kessler L, Nader M, Bartel T, Leyser S, Barbato F, Schuler M, Bauer S, Siveke JT, Herrmann K, Hamacher R, Fendler WP. Lanzafame H, et al. J Nucl Med. 2024 May 9:jnumed.123.267248. doi: 10.2967/jnumed.123.267248. Online ahead of print. J Nucl Med. 2024. PMID: 38724279
Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial).
Nikitas J, Lam E, Booker KA, Fendler WP, Eiber M, Hadaschik B, Herrmann K, Hirmas N, Lanzafame H, Stuschke M, Czernin J, Steinberg ML, Nickols NG, Kishan AU, Calais J. Nikitas J, et al. Among authors: lanzafame h. J Nucl Med. 2024 Apr 25:jnumed.123.267004. doi: 10.2967/jnumed.123.267004. Online ahead of print. J Nucl Med. 2024. PMID: 38664019
Diagnostic Accuracy of 68Ga-FAPI Versus 18F-FDG PET in Patients with Various Malignancies.
Hirmas N, Hamacher R, Sraieb M, Kessler L, Pabst KM, Barbato F, Lanzafame H, Kasper S, Nader M, Kesch C, von Tresckow B, Hautzel H, Aigner C, Glas M, Stuschke M, Kümmel S, Harter P, Lugnier C, Uhl W, Hadaschik B, Grünwald V, Siveke JT, Herrmann K, Fendler WP. Hirmas N, et al. Among authors: lanzafame h. J Nucl Med. 2024 Feb 8:jnumed.123.266652. doi: 10.2967/jnumed.123.266652. Online ahead of print. J Nucl Med. 2024. PMID: 38331453
Head-to-Head Comparison of FDG and Radiolabeled FAPI PET: A Systematic Review of the Literature.
Guglielmo P, Alongi P, Baratto L, Abenavoli E, Buschiazzo A, Celesti G, Conte M, Filice R, Gorica J, Jonghi-Lavarini L, Lanzafame H, Laudicella R, Librando M, Linguanti F, Mattana F, Miceli A, Olivari L, Piscopo L, Romagnolo C, Santo G, Vento A, Volpe F, Evangelista L. Guglielmo P, et al. Among authors: lanzafame h. Life (Basel). 2023 Aug 28;13(9):1821. doi: 10.3390/life13091821. Life (Basel). 2023. PMID: 37763225 Free PMC article. Review.
The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy.
Adebahr S, Althaus A, Scharl S, Strouthos I, Farolfi A, Serani F, Lanzafame H, Trapp C, Koerber SA, Peeken JC, Vogel MME, Vrachimis A, Spohn SKB, Grosu AL, Kroeze SGC, Guckenberger M, Fanti S, Hruby G, Emmett L, Belka C, Schmidt-Hegemann NS, Henkenberens C, Aebersold DM, Wiegel T, Afshar-Oromieh A, Zamboglou C, Shelan M. Adebahr S, et al. Among authors: lanzafame h. Eur J Nucl Med Mol Imaging. 2024 Jan;51(2):558-567. doi: 10.1007/s00259-023-06438-3. Epub 2023 Sep 22. Eur J Nucl Med Mol Imaging. 2024. PMID: 37736808 Free PMC article.
14 results